Slow Parkinson degeneration using Dserine
- Trial ID
- NCT07312110
- Official Title
- D-SPARK: A Randomized Double Blind Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression
- Goal
- Slow Parkinson degeneration using Dserine
- Phase
- PHASE2
- Status
- RECRUITING
- Sponsor
- Haukeland University Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 100 participants
- Conditions
- Parkinson s Disease, Parkinson Disease (PD)
- Interventions
- D-serine, Placebo
Plain-Language Summary
The goal is to find out whether D-serine can slow Parkinson's progression by boosting glutamate-driven synaptic function and helping protect neurons, not just treating symptoms. D-serine is a natural co-agonist at NMDA receptors, it enhances NMDA receptor signaling to support synaptic plasticity and neuronal health, and it will be tested against placebo while participants stay on stable Parkinson's meds. The trial seeks people 40 to 80 years old diagnosed within the last 5 years with DaTscan-confirmed PD and Hoehn and Yahr under 3, on stable symptomatic treatment; dementia, atypical parkinsonism, significant kidney disease, recent D-serine use, and other serious medical or psychiatric issues are exclusions.
Locations
- Sørlandet Hospital Arendal, Arendal, Agder, Norway
- Akershus University Hospital, Lørenskog, Akershus, Norway
- Vestre Viken Hospital, Drammen, Buskerud, Norway
- Molde Hospital, Molde, Møre og Romsdal, Norway
- Bodø Hospital (Nordland Hospital), Bodø, Nordland, Norway
- Oslo University Hospital, Oslo, Oslo County, Norway
- Haugesund Hospital, Haugesund, Rogaland, Norway
- University Hospital of North Norway, Tromsø, Troms, Norway
- Haukeland University Hospital, Bergen, Vestland, Norway
- Førde Hospital, Førde, Vestland, Norway
- Østfold Hospital, Sarpsborg, Østfold fylke, Norway
Frequently Asked Questions
- What is this trial testing?
- This trial is studying D-serine. The goal is to find out whether D-serine can slow Parkinson's progression by boosting glutamate-driven synaptic function and helping protect neurons, not just treating symptoms. D-serine is a natural co-agonist at NMDA receptors, it enhances NMDA receptor signaling to support synaptic plasticity and neuronal health, and it will be tested against placebo while participants stay on stable Parkinson's meds. The trial seeks people 40 to 80 years old diagnosed within the last 5 years with DaTscan-confirmed PD and Hoehn and Yahr under 3, on stable symptomatic treatment; dementia, atypical parkinsonism, significant kidney disease, recent D-serine use, and other serious medical or psychiatric issues are exclusions.
- Who can participate?
- Participants must be between 40 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 11 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 2 trial is estimated to last approximately 2 years and 2 months.